July 30 Biotech Update

The sector is pretty weak, which is a continuation of the past couple of days. It is not immediately clear to me the reason for the weakness as earnings have.

July 29 Biotech Update

The sector was a strong performer after the bell but it did not seem to last long. The sector should be strong given the bulk of the earnings but I.

July 28 Biotech Update

The sector looked like it would be off to a good start but it faded quickly. I would still argue that any movement before the GILD earnings can be quickly.

July 27 Biotech Update

The market looks bad and it is bringing down the sector although I think BIIB has done a pretty good job at reversing some bullish biotech sentiment. That being said.

BioBlast Pharma: an under the radar ultra-rare disease company

  Bio Blast Pharma Ltd. (ORPN) – Nasdaq BioBlast Pharma (ORPN) is a clinical-stage biotech company, focused on treatments for rare and ultra-rare diseases, especially genetic and metabolic diseases. The company has three.

July 24 Biotech Update

Unlike earlier this week where bad news was shrugged off, it looks like we are going to see selling on the bad news. This pullback should eventually generate nice bargains.

July 23 Biotech Update

A good start to the day with earnings almost universally beats and raises. Given the strength the sector showed yesterday, this should move the group higher and increase expectations for.

July 22 Biotech Update

The sector is a little weak this morning, which is to be expected but not nearly as weak as I thought it would be going into the open. There has.

July 21 Biotech Update

The sector was green again yesterday and this morning but it does not seem to be a broad based move. The small caps appear to be underperforming and among the.

July 20 Biotech Update

There is some news this morning but nothing that in and of itself is likely to move the sector. On the other hand, the news has generally been positive, so.

July 17 Biotech Update

I leave town and the sector runs to new all-time highs and I come back and there is a pullback. Perhaps the market is trying to tell me something. It.

TRIL – Preparing For The Next Move Upward

  Trillium Therapeutics Inc. (TRIL) – Nasdaq Trillium (TRIL) is developing the next-generation of cancer immunotherapies. TRIL’s lead program, SIRPαFc, targets CD47 to prevent cancer cells from delivering a “do not eat”.

July 9 Biotech Update

It is a new day and apparently a new market with everything now OK. Clearly chop is the order of the summer (as is amnesia with the market having almost.

July 8 Biotech Update

We end one macro crisis and head directly into another. China, however, is more important than Greece so this makes a little more sense but even this selling is likely.

Catalyst Watch – Vol. 3, Edition 9 (7/8/15)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

July 7 Biotech Update

There is a little more news today but still relatively quiet. The market seems to be looking for a direction but the sector seems to be outperforming to the upside..

July 6 Biotech Update

A pretty quiet start to the week (at least in terms of bio news). Obviously we have all the Greek drama but despite fears of the worst, the opening was.

July 3 Biotech Update

This is the last note before the fourth and I wanted to spend time going into a new therapeutic space and highlight a new company (well, it is new to.

July 1 Biotech Update

I am back from vacation and ready to get back into the sector. I planned on talking about the CGPR space today but I will push that back until tomorrow.

June 18 Biotech Update

The summer is seasonally weak, especially after the EHA and ASCO- right? I am not sure of the exact catalyst for the move today but it is certainly moving the.

June 17 Biotech Update

Market doing a little better but biotechs seemed to take yesterday off despite the broader rally. The sector seems to be more positive today (there were certainly bright spots yesterday.

June 16 Biotech Update

The market is quite resilient. While we did not get a full reversal yesterday, the market came back and biotechs seemed to outperform. This morning is off to a good.

June 15 Biotech Update

It is a macro world and we are just living in it. Sunday night we should have known this was going to be a bad start to the week with.

The Reality for Mannkind

Mannkind, the maker of the inhaled insulin product Afrezza, is the 11th best performing biotech stock according to Finviz in the last month, up 62%. That performance is in line.

June 12 Biotech Update

The market is not happy this morning and it is not immediately clear as to the “cause.” This is taking the sector down, especially some of the recent fliers. The.

June 10 Biotech Update

This is sort of a different start to the day with the market off to a good start but biotechs the obvious laggard. The sector had been one of the.

June 9 Biotech Update

The market continues to sell off with biotechs seemingly able to levitate but still weak this morning. Either the market is going to reverse in the near term or it.

June 8 Biotech Update

The sector is quiet and macro seems neutral if not slightly negative but it is early. There is not a lot of news to discuss. I suspect that the trend.

June 5 Biotech Update

Not much going on except broad and general selling (at least early). It seems like we are in one of those bizarro times where good economic data are bad for.

June 4 Biotech Update

The sector is not doing great but also not significantly pulling back (broader market is lower but also pretty choppy). The large caps appeared weak again and this is still.

June 3 Biotech Update

Yesterday was not a great day for the sector with reports of a large sell program in large caps and from what I saw that makes sense. None of the.

Browsing 31 / 2 articles